Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Laborértékek

• Study or Fellow Eye:
  • Prior gene therapy, either eye
  • Any active ocular/intraocular infection or inflammation (e.g., blepharitis, infectious conjunctivitis, keratitis, scleritis, uveitis) or history of idiopathic or autoimmune-associated uveitis, either eye
  • History of retinal disease other than wAMD or PCV, study eye
  • Any condition preventing visual acuity improvement (e.g., fibrosis, atrophy, or retinal epithelial tear in the center of the fovea), study eye.
  • History of (or active) retinal detachment, study eye
  • Uncontrolled glaucoma (defined as IOP > 25 mmHg despite treatment), study eye, or history of steroid-response ocular hypertension/glaucoma in either eye
  • History of intravitreal therapy, (other than anti-VEGF therapy) such as intravitreal steroid injection or investigational product, in the 6 months prior to screening, study eye
  • Any prior treatment with photodynamic therapy or laser photocoagulation, study eye
  • History of glaucoma filtration, vitrectomy, or other procedure that could affect drug distribution or clearance, study eye.

• General:
  • Must be willing and able to provide written, signed informed consent.
  • Age: Subjects ≥ 50 and ≤ 89 years of age at the time of signing the informed consent
  • Study eye:
  • Diagnosis of wAMD, including symptomatic macular PCV, confirmed by the Central Reading Center
  • The macular neovascularization lesion must be confirmed as determined by the Central Reading Center based on SD-OCT imaging at screening.
  • BCVA ≤ 20/25 and ≥ 20/250 (≤ 80L and ≥ 30L ETDRS letters)
  • History of ≥ 2 anti-VEGF injections prior to trial entry with meaningful response to anti-VEGF and continued need for anti-VEGF treatment
  • Response to anti-VEGF at trial entry